Discovery Platform

Sapience programs focus on discovery and development of peptides that act at the level of transcriptional regulation of oncogenic and immune-modulatory proteins by disrupting protein-protein interactions. Sapience has multiple approaches to discovering these new molecular entities, including our library-based platform screen that uses Protein Fragment Complementation enhanced with a Competitive and Negative Design Initiative (PCA-CANDI) that we run in partnership with the University of Bath, and our Knowledge Based Design Initiative (KBDI).


Protein fragment complementation that incorporates competitive and negative design elements allows for rapid discovery of peptide disrupters of specific protein-protein interactions.

ST201 emerged from the PCA-CANDI platform.

Schematic of PCA:

Knowledge Based Design Initiative

Rational design of peptide libraries to disrupt protein-protein interactions; the basis of which may be 3D modeling or hits from PCA-CANDI.

ST101 is an example of Sapience’s KBDI. It was discovered and initiated IND-enabling manufacturing within 9 months of library initiation.

Schematic of KBDI: